In the current work we have utilized our access to the CAS Content Collection consisting of over 204 million substances 32 to identify substances showing the presence of warhead groups and thereby capable of acting as covalent drugs/inhibitors. We chose to look at ~33 warhead groups across a wide range of reactivities and analyze our dataset of identified substances/compounds to provide a fuller perspective on the topic. Warheads included in this analysis range from the most used ones (α, β unsaturated carbonyls and their derivatives) to the more obscure ones (such as Selenium-based warheads). In this report we present analysis of published research (journals and patents) pertaining to the chosen warheads. We also looked at FDA approved covalent inhibitors as well as those currently in various stages of clinical trials. Our aim with such a detailed and extensive warhead-specific analysis was to provide insights with respect to substructure preference relative to warhead (as well as protein target where possible).